Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christophe Moreno

Showing results (131-140 of 194) with videos related to

Pageof 20
Sort By:
Diabetes|September 21, 2017
JNK Activation of BIM Promotes Hepatic Oxidative Stress, Steatosis, and Insulin Resistance in ObesitySara A Litwak, Lokman Pang, Sandra Galic, et al.
BMC Gastroenterology|February 12, 2017
Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infectionStefan Bourgeois, Hans Van Vlierberghe, Christophe Moreno, et al.
Transplantation|May 9, 2009
Acute liver transplant rejection upon immunosuppression withdrawal in a tolerance induction trial: potential role of IFN-gamma-secreting CD8+ T cellsVincent Donckier, Ligia Craciun, Valerio Lucidi, et al.
Translational Gastroenterology and Hepatology|February 13, 2025
Co-existing regeneration mechanisms in severe alcohol-related steatohepatitisAdrienne Lejeune, Peter Stärkel, Alexandre Louvet, et al.
United European Gastroenterology Journal|June 6, 2023
Questionnaire PLD-complaint-specific assessment identifies need for therapy in polycystic liver disease: A multi-centric prospective studyAntoon Billiet, Frederik Temmerman, Walter Coudyzer, et al.
The American Journal of Gastroenterology|September 1, 2021
Ledipasvir/Sofosbuvir for 8, 12, or 24 Weeks in Hepatitis C Patients Undergoing Dialysis for End-Stage Renal DiseaseWan-Long Chuang, Tsung-Hui Hu, Peter Buggisch, et al.
Hepatology (Baltimore, Md.)|January 30, 2019
JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-Infected Patients Without Cirrhosis: OMEGA-1Stefan Zeuzem, Stefan Bourgeois, Susan Greenbloom, et al.
Journal of Hepatology|November 24, 2022
Low alcohol consumption influences outcomes in individuals with alcohol-related compensated cirrhosis in a French multicenter cohortAlexandre Louvet, Valérie Bourcier, Isabelle Archambeaud, et al.
European Journal of Gastroenterology & Hepatology|January 18, 2013
Hepatitis B virus and hepatitis C virus infections in Belgium: similarities and differences in epidemics and initial managementBénédicte De Vroey, Christophe Moreno, Wim Laleman, et al.
Hepatology (Baltimore, Md.)|March 26, 2019
A 17-Beta-Hydroxysteroid Dehydrogenase 13 Variant Protects From Hepatocellular Carcinoma Development in Alcoholic Liver DiseaseJie Yang, Eric Trépo, Pierre Nahon, et al.
Pageof 20

Showing results (131-140 of 194) with videos related to

Sort By:
Pageof 20
Diabetes|September 21, 2017
JNK Activation of BIM Promotes Hepatic Oxidative Stress, Steatosis, and Insulin Resistance in ObesitySara A Litwak, Lokman Pang, Sandra Galic, et al.
BMC Gastroenterology|February 12, 2017
Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infectionStefan Bourgeois, Hans Van Vlierberghe, Christophe Moreno, et al.
Transplantation|May 9, 2009
Acute liver transplant rejection upon immunosuppression withdrawal in a tolerance induction trial: potential role of IFN-gamma-secreting CD8+ T cellsVincent Donckier, Ligia Craciun, Valerio Lucidi, et al.
Translational Gastroenterology and Hepatology|February 13, 2025
Co-existing regeneration mechanisms in severe alcohol-related steatohepatitisAdrienne Lejeune, Peter Stärkel, Alexandre Louvet, et al.
United European Gastroenterology Journal|June 6, 2023
Questionnaire PLD-complaint-specific assessment identifies need for therapy in polycystic liver disease: A multi-centric prospective studyAntoon Billiet, Frederik Temmerman, Walter Coudyzer, et al.
The American Journal of Gastroenterology|September 1, 2021
Ledipasvir/Sofosbuvir for 8, 12, or 24 Weeks in Hepatitis C Patients Undergoing Dialysis for End-Stage Renal DiseaseWan-Long Chuang, Tsung-Hui Hu, Peter Buggisch, et al.
Hepatology (Baltimore, Md.)|January 30, 2019
JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-Infected Patients Without Cirrhosis: OMEGA-1Stefan Zeuzem, Stefan Bourgeois, Susan Greenbloom, et al.
Journal of Hepatology|November 24, 2022
Low alcohol consumption influences outcomes in individuals with alcohol-related compensated cirrhosis in a French multicenter cohortAlexandre Louvet, Valérie Bourcier, Isabelle Archambeaud, et al.
European Journal of Gastroenterology & Hepatology|January 18, 2013
Hepatitis B virus and hepatitis C virus infections in Belgium: similarities and differences in epidemics and initial managementBénédicte De Vroey, Christophe Moreno, Wim Laleman, et al.
Hepatology (Baltimore, Md.)|March 26, 2019
A 17-Beta-Hydroxysteroid Dehydrogenase 13 Variant Protects From Hepatocellular Carcinoma Development in Alcoholic Liver DiseaseJie Yang, Eric Trépo, Pierre Nahon, et al.
Pageof 20